论文部分内容阅读
[Background] Alzheimers disease (AD) is a progressive neurodegenerative disorder that affects the elderly.Clinical studies have found that the amyloid deposits in the brain are aggravated along with the deterioration of the AD pathology.Indeed,Aβ peptides change particularly significantly early in the preclinical stage, and then detection of Aβ is of great importance in early diagnosis.Therefore, it is critical to diagnose and treat AD at the preclinical stage, and Aβ becomes the key target of international research.We also focus on risk factors for preclinical Alzheimers disease (PCAD), especially imbalance in lipid metabolism.[Objective] whether deficiency of phospholipid transfer protein (PLTP) in lipid metabolism acts as a risk factor and participates in the pathological process of AD through regulating APP metabolism.